Raily Aesthetic Medicine International Holdings Limited Issues Profit Alert: Significant Turnaround Expected for FY2025

Key Highlights

• Expected Sharp Reduction in Net Loss: The Group anticipates recording a net loss of approximately RMB2 million for the year ended 31 December 2025, compared to a much larger net loss of about RMB63 million for the year ended 31 December 2024.
• Return to Profitability for Shareholders: Notably, profit attributable to owners of the parent is expected to reach approximately RMB2 million for 2025, in stark contrast to a loss of about RMB59 million in 2024. This marks a significant turnaround in the company’s financial results.
• Absence of One-Off Impairment Losses: The improved results for 2025 are mainly attributed to the absence of one-off impairment losses that adversely affected the 2024 financial year.
• Improvement in Profit Margins: The company also reported an improvement in overall operational profit margins, contributing to the better performance in 2025.

Details for Shareholders and Investors

Raily Aesthetic Medicine International Holdings Limited (Stock Code: 2135) has issued a profit alert to inform shareholders and potential investors of a marked improvement in its financial performance for the year ended 31 December 2025. Based on a preliminary assessment of unaudited management accounts and information currently available to the Board, the Group expects:

• A significant reduction in losses at the Group level, from RMB63 million in 2024 to about RMB2 million in 2025.
• The attributable net profit to shareholders is forecasted to swing from a loss of RMB59 million in 2024 to a profit of approximately RMB2 million in 2025. This positive reversal is notable and may be viewed favorably by the market.

The company highlighted that the expected improvement is primarily due to the absence of one-off impairment losses that impacted the previous year’s results. Additionally, there has been a notable enhancement in profit margins across the Group’s operations, further supporting this financial turnaround.

Matters of Potential Price Sensitivity

• Profit Alert and Turnaround: The shift from a significant loss to a small profit attributable to shareholders is material and could have a substantial impact on the company’s share price, as it signals a turnaround in financial health and operational efficiency.
• Pending Final Results: Investors should note that the current figures are based on preliminary, unaudited management accounts. The final audited results are expected to be published by the end of March 2026. Adjustments may occur during the audit process.
• Advisory for Shareholders: The company has reiterated that shareholders and potential investors should exercise caution when dealing in the shares of the Company, given the preliminary nature of the information.

Corporate Governance and Board Composition

As of the date of the announcement (4 March 2026), the Board comprises the following members:

• Mr. Fu Haishu (Chairman and Executive Director)
• Mr. Song Jianliang (Executive Director)
• Mr. Wang Ying (Executive Director)
• Mr. Cao Dequan (Independent Non-executive Director)
• Ms. Yang Xiaofen (Independent Non-executive Director)
• Mr. Liu Teng (Independent Non-executive Director)

Next Steps

The company is in the process of finalising its consolidated annual results for the year ended 31 December 2025. The official annual results announcement is expected by the end of March 2026, in compliance with the Hong Kong Listing Rules.

Conclusion

This profit alert indicates a notable turnaround in Raily Aesthetic Medicine International Holdings Limited’s financial performance. The return to profitability for shareholders and the significant reduction in overall losses are key highlights that may influence investor sentiment and share price movement. However, investors are reminded that these figures are preliminary and subject to audit adjustments.

Disclaimer: This article is based on preliminary unaudited information disclosed by Raily Aesthetic Medicine International Holdings Limited and is intended for informational purposes only. Investors are advised to exercise caution and refer to the company’s official audited results and disclosures before making any investment decisions. The information herein does not constitute investment advice.

View RAILY AESMED Historical chart here